Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
home:othertreatments:antibacterials:betalactams [10.25.2018] – [Cephalosporins] sallieqhome:othertreatments:antibacterials:betalactams [09.14.2022] (current) – external edit 127.0.0.1
Line 3: Line 3:
 The Beta-lactam antibiotics are a broad class of antibiotics that includes the penicillins and the cephalosporins. Ceftriaxone (Rocephin), a cephalosporin, is sometimes given intravenously to patients with Lyme disease. The Beta-lactam antibiotics are a broad class of antibiotics that includes the penicillins and the cephalosporins. Ceftriaxone (Rocephin), a cephalosporin, is sometimes given intravenously to patients with Lyme disease.
  
-The Beta-lactams are ineffective against the pathogens which cause chronic disease as they can't enter into human cells,(({{pubmed>long:21297670}})) but perhaps more importantly actually foster the growth of L-form bacteria.+The Beta-lactams are ineffective against the pathogens which cause chronic disease as they can't enter into human cells,(({{pmid>long:21297670}})) but perhaps more importantly actually foster the growth of L-form bacteria.
  
 Patients who are offered penicillin antibiotics to treat strep or other acute infections should ask for an alternative such as claforan (Cefotaxime). Patients who are offered penicillin antibiotics to treat strep or other acute infections should ask for an alternative such as claforan (Cefotaxime).
 +
 ===== Penicillins including amoxicillin ===== ===== Penicillins including amoxicillin =====
  
Line 12: Line 13:
 <blockquote>Clinical persistence of //Borrelia burgdorferi// in patients with active Lyme borreliosis occurs despite obviously adequate antibiotic therapy.... <blockquote>Clinical persistence of //Borrelia burgdorferi// in patients with active Lyme borreliosis occurs despite obviously adequate antibiotic therapy....
  
- //**V. Mursic**, et al.// (({{pubmed>long:8811359}}))</blockquote>+ //**V. Mursic**, et al.// (({{pmid>long:8811359}}))</blockquote>
  
 In fact, Lida Mattman, who authored what remains the definitive textbook on L-form bacteria describes how to "induce"  the bacterial forms in a penicillin medium: In fact, Lida Mattman, who authored what remains the definitive textbook on L-form bacteria describes how to "induce"  the bacterial forms in a penicillin medium:
Line 18: Line 19:
 <blockquote>One hour after placing Proteus in a penicillin medium, the nuclear material may gather into one or two chromatin granules which gradually proliferate to form a small peripheral wreath.... As Hirokawa cultured //E. coli// in penicillin broth, the DNA content per cell increased more than 4 times in 3 h.... <blockquote>One hour after placing Proteus in a penicillin medium, the nuclear material may gather into one or two chromatin granules which gradually proliferate to form a small peripheral wreath.... As Hirokawa cultured //E. coli// in penicillin broth, the DNA content per cell increased more than 4 times in 3 h....
  
- //**Lida Mattman, PhD**// ((Mattman, L.H. (2000). //Cell wall deficient forms.// Third edition, [[http://books.google.com/books?id=mincr2Hi81UC&pg=PA23&vq=penicillin&dq=beta-lactam+lida+mattman+cell+wall+deficient&source=gbs_search_s&cad=0|p. 23]].))</blockquote>+ //**Lida Mattman, PhD**// ((Mattman, L.H. (2000). //Cell wall deficient forms.// Third edition, [[https://books.google.com/books?id=mincr2Hi81UC&pg=PA23&vq=penicillin&dq=beta-lactam+lida+mattman+cell+wall+deficient&source=gbs_search_s&cad=0|p. 23]].))</blockquote>
  
 Later in her textbook Mattman writes: Later in her textbook Mattman writes:
Line 32: Line 33:
 concentrations from 1.0 to 5000 U/ml induced the L-phase of Staphylococci. concentrations from 1.0 to 5000 U/ml induced the L-phase of Staphylococci.
  
- //**Lida Mattman, PhD**// ((Mattman, L.H. (2000). //Cell wall deficient forms.// Third edition, [[http://books.google.com/books?id=mincr2Hi81UC&pg=PA23&vq=penicillin&dq=beta-lactam+lida+mattman+cell+wall+deficient&source=gbs_search_s&cad=0#PPA82,M1|p. 84]].))</blockquote>+ //**Lida Mattman, PhD**// ((Mattman, L.H. (2000). //Cell wall deficient forms.// Third edition, [[https://books.google.com/books?id=mincr2Hi81UC&pg=PA23&vq=penicillin&dq=beta-lactam+lida+mattman+cell+wall+deficient&source=gbs_search_s&cad=0#PPA82,M1|p. 84]].))</blockquote>
  
 ===== Cephalosporins ===== ===== Cephalosporins =====
Line 38: Line 39:
 <relatedarticle> [[home:othertreatments:antibacterials:highdose|High-dose antibiotics]] </article> <relatedarticle> [[home:othertreatments:antibacterials:highdose|High-dose antibiotics]] </article>
  
-Patients with Lyme disease are often given high doses of intravenous ceftriaxone (Rocephin) and without any indication that the treatment is effective – even in the short-term.(({{pubmed>long:17928580}})) In fact, Rocephin only contributes to disease over the long-term.+Patients with Lyme disease are often given high doses of intravenous ceftriaxone (Rocephin) and without any indication that the treatment is effective – even in the short-term.(({{pmid>long:17928580}})) In fact, Rocephin only contributes to disease over the long-term.
  
 {{section>:home:othertreatments:antibacterials:highdose#high-dose_ceftriaxone_rocephin_is_ineffective&firstseconly&noheader}} {{section>:home:othertreatments:antibacterials:highdose#high-dose_ceftriaxone_rocephin_is_ineffective&firstseconly&noheader}}
 +
  
 {{tag>Other_medication}} {{tag>Other_medication}}
Line 47: Line 49:
  
  
 +
 +<nodisp>
 ===== Notes and comments ===== ===== Notes and comments =====
  
-FDA restricts use of cephalosporin antibiotics in livestock saying it contributes to drug-resistant bacteria in humans. http://nyti.ms/yhomPV +FDA restricts use of cephalosporin antibiotics in livestock saying it contributes to drug-resistant bacteria in humans. https://nyti.ms/yhomPV 
-===== References =====+===== References =====</nodisp> 
home/othertreatments/antibacterials/betalactams.1540511688.txt.gz · Last modified: 10.25.2018 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.